NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression [Yahoo! Finance]
Neuronetics, Inc. (STIM)
Last neuronetics, inc. earnings: 3/3 06:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
MALVERN, Pa., March 25, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced clearance from the U.S. Food and Drug Administration (FDA) for NeuroStar Advanced Therapy for use as an adjunct for the treatment of major depressive disorder (MDD) in adolescent patients aged 15-21. NeuroStar is the first and only transcranial magnetic stimulation (TMS) treatment FDA-cleared for this age group, making it the fourth FDA-cleared indication for NeuroStar. "The prevalence of depression in adolescents and young adults has been accelerating since the COVID-19 pandemic. The current treatment options available for adolescents are extremely limited, compared to those available for adults," according to Dr. Kenneth Pages, Medical Director of TMS of South Tampa. "NeuroStar's TMS therapy now offers a promising first-
Show less
Read more
Impact Snapshot
Event Time:
STIM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STIM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STIM alerts
High impacting Neuronetics, Inc. news events
Weekly update
A roundup of the hottest topics
STIM
News
- GREENBROOK TMS REPORTS FISCAL YEAR 2023 OPERATIONAL AND FINANCIAL RESULTS [Yahoo! Finance]Yahoo! Finance
- Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call [Yahoo! Finance]Yahoo! Finance
- Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference CallGlobeNewswire
- New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital [Yahoo! Finance]Yahoo! Finance
- New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is VitalGlobeNewswire
STIM
Earnings
- 3/5/24 - Beat
STIM
Sec Filings
- 4/11/24 - Form DEFA14A
- 4/11/24 - Form DEF
- 4/1/24 - Form SC
- STIM's page on the SEC website